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Abstract Background: Safety is a primary concern with contrast agents used for MRI.
If precautions could be taken before the repeated administration of gadolinium-
based contrast media, then the awareness and management of adverse reac-
tions would be more efficient.
Objectives: To assess the safety and efficacy of gadoterate meglumine (Gd-
DOTA) [Magnescope in Japan, Dotarem in other countries], a gadolinium-
based contrast agent, in patients undergoing imaging of the brain/spinal cord
and/or trunk/limbs, and to identify factors associated with the onset of ad-
verse reactions.
Methods: The study ran for 4 years and included 3444 cases. The study was
conducted before it became known that gadolinium-based contrast agents
could trigger the development of nephrogenic systemic fibrosis. Patients for
whom the contrast agent was indicated and who underwent imaging of the
brain/spinal cord and/or trunk/limbs by MRI were enrolled. There were 1300
inpatients who were followed up during hospitalization (for several days),
and 2144 outpatients who were followed up for at least 2 hours on-site. After
Gd-DOTA administration, 13 patient baseline characteristics were used to
explore factors that might predict a greater likelihood of acute non-renal
adverse reactions. The physician’s appraisal of the efficacy of Gd-DOTA was
also assessed.
Results:A total of 40 adverse reactions were recorded in 32 patients, giving an
overall incidence of adverse reactions of 0.93%. Gastrointestinal disorders
were the most commonly reported adverse reactions (0.49%). Most adverse
reactions reported were of mild intensity and no serious adverse reactions
were reported. This study found that statistically significant risk factors for
adverse reactions were general patient condition, liver disorder, kidney dis-
order, health complications, concomitant treatments, and Gd-DOTA dose
(although the incidence of adverse reactions was not dose dependent). In the
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majority of cases (99.53%), the efficacy of Gd-DOTA was rated as ‘effective’
or ‘very effective’; only the presence of kidney disorder was associated with a
significantly greater likelihood of Gd-DOTA inefficacy.
Conclusion:Overall, this post-marketing surveillance study did not reveal any
untoward or unexpected findings concerning the safety or efficacy of Gd-
DOTA. The low incidence of adverse reactions (<1%) and the absence of
serious adverse reactions reported during the survey period showed that Gd-
DOTA was very well tolerated. The use of Gd-DOTA as an MRI-enhancing
contrast medium in the clinical practice setting appears to be safe and effective.
Introduction
MRI is used for imaging of internal body tissues
and organs, and provides excellent tissue contrast.
However, improved contrast enhancement can be
achieved by the use of contrast media, which has
greatly enhanced the diagnostic accuracy of this
imaging modality.
Gadolinium, which is widely used as a contrast
agent, is intrinsically toxic, in part, by blocking
calcium channels. Gadolinium must be chelated
with an appropriate ligand to allow clinical use.
These gadolinium complexes can be linear or
macrocyclic.[1] Extracellular gadolinium-chelates
are distributed throughout the extracellular space
without crossing the normal blood-brain barrier,
and are therefore efficient for detecting patho-
logic abnormalities, including brain metastases as
well as detailed characterization of parenchymal
lesions and lymph nodes. The clinical benefit as-
sociated with the use of gadolinium-chelates has
been clearly established over the last 20 years.[2-6]
Most gadolinium-based agents are excreted by
the kidneys, but elimination becomes problema-
tic for individuals with reduced kidney function.[7]
Gadolinium-containing contrast agents are rapidly
cleared with a half-life of approximately 2 hours in
patients with normal renal function, while in those
with chronic renal failure this clearance may ex-
ceed 30–120 hours.[8]
A primary concern with all MRI contrast
agents is safety. The safety profile of gadolinium-
based contrast agents seems to be superior to that
of iodinated contrast molecules used for x-ray
based procedures.[9] Minor adverse effects asso-
ciated with gadolinium-based agents include nau-
sea, headache, and taste perversion.[9] A number
of gadolinium agents are available and although
they cannot be distinguished on the basis of their
mild adverse effects, recent studies have high-
lighted chelate stability and safety issues.[9] There-
fore, the stability of gadolinium-contrast agents
seems to be an important factor in the pathogene-
sis of the serious complication of nephrogenic
systemic fibrosis (NSF), and, in particular, clini-
cal observations associated with the least stable
of gadolinium-contrast agents. Importantly, it
was demonstrated in 2006 that some gadolinium-
based contrast agentsmay trigger the development
of NSF in patients with impaired renal function.[8]
Consequently, the European Medicines Agency
(EMA) ruled that the use of gadodiamide, gado-
versetamide, and gadopentate dimeglumine in
patients with a glomerular filtration rate (GFR)
<30mL/min/1.73m2 was contraindicated and that
these agents should only be used with caution in
patients with moderately reduced kidney func-
tion (30–60mL/min/1.73m2).
Among the gadolinium-based contrast media
available in clinical practice, gadoterate meglumine
(Gd-DOTA, Magnescope in Japan, Dotarem
in other countries), a cyclic ionic gadolinium che-
late, is approved for imaging cerebral and spinal
lesions with abnormal blood-brain barrier or anom-
alous vascularity as well as for body imaging. Gd-
DOTA has the highest thermodynamic stability
(log10 KTHERM = 25.6), apparent stability (log10
Kcond= 19.3), kinetic stability, and decomplexation
of all available gadolinium-chelate complexes.[1,9-12]
The safety profile of Gd-DOTA has recently been
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established in a German post-marketing surveil-
lance study involving more than 24 000 patients
who underwent routine MRI examinations.[13]
The German study aimed to assess the diagnostic
value and safety of Gd-DOTA in clinical prac-
tice, but did not identify the factors that may in-
crease the risk of adverse reactions.
The aim of this Japanese post-marketing sur-
veillance studywas to assess the safety and efficacy
of Gd-DOTA (registered in Japan in September
2000) in patients undergoing MRI, and to iden-
tify factors associated with the onset of adverse
reactions. This type of evaluation, mandatory in
Japan, is designed to confirm the safety and effi-
cacy of any new drug in several conditions in
which the product is routinely used, in contrast
with the pre-market, development phase.
Methods
Study Design and Patient Enrollment
Conditions
This post-marketing surveillance study was
conducted according to the protocol submitted
by Eiken Chemical Co., Ltd (Tokyo, Japan) in
accordance with the Pharmaceutical Affairs Law
of Japan. The Pharmaceutical Affairs Act set up
a drug re-examination system (i.e. a system that
ensures marketers will report on safety and ef-
fectiveness of the contrast agents/drugs used in
routine medical practice), which usually collects
data 6 years after the launch of any product.
As a part of this Act, marketers were in-
structed by the Ministry of Health, Labor and
Welfare to conduct a ‘‘drug use-results survey’’
during that period. A guideline for ‘‘drug use-
results survey’’ implementation method defines
that marketers shall collect a minimum of 3000
cases during the 3 years after product launch, and
its purpose is to assure safety and effectiveness of
routine medical treatment or administration of
contrast agents.
Therefore, our post-marketing surveillance
study was planned to run for at least 3 years fol-
lowing the Japanese launch in April 2001 of the
Gd-DOTA vials and syringes (Guerbet, Roissy
CdG Cedex, France) and was designed to enroll
at least 3000 inpatients and/or outpatients. A
continuous surveillance process was followed
whereby patients who had been administered Gd-
DOTA were registered consecutively until the
cases reached the agreed numbers and the defined
period of recruitment mentioned in the contract
with each hospital site. Informed consent was
considered unnecessary for this post-marketing
surveillance study.
Patients for whom the contrast agent was indi-
cated and who underwent imaging of the brain/
spinal cord and/or trunk/limbs by MRI were
enrolled.
Baseline Characteristics
Demographic characteristics (sex, age, weight)
and clinical characteristics (patient status [inpatient/
outpatient], indications for imaging, general con-
dition, health complications, concomitant drugs),
as well as Gd-DOTA dose, premedication, and
medical history (liver disorder, kidney disorder,
history of allergy/adverse reactions to drugs) were
obtained. General condition and complication
were determined by the physician’s appraisal at
each site. No specific laboratory tests were required,
but if patients had liver disorder and/or kidney
disorder, the reports of the following tests con-
ducted in routine medical practice were obtained:
AST, ALT, alkaline phosphatase (ALP), lactate
dehydrogenase (LDH), and g-glutamyl trans-
ferase (g-GT), total bilirubin for liver disorders,
and serum creatinine and blood urea nitrogen
(BUN) for kidney disorders.
Safety Evaluation
After administration of Gd-DOTA, adverse
events for outpatients were recorded up to at least
2 hours on-site or until they left the MRI suite,
and inpatients were followed up for several days
(during their hospitalization). Every adverse event
occurring during observation in routine medical
practice was recorded in the case report form.
Patient baseline characteristics were used to
explore factors that might predict a greater like-
lihood of acute non-renal adverse reactions. Late
and very late adverse reactions were not system-
atically studied.
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In addition, the main subsets of patients who
were submitted to specific surveillance for adverse
reactions were: (i) those who received Gd-DOTA
>0.1mL/kg in whom the kidney was the imaging
target; (ii) those with decreased kidney function;
(iii) those with decreased liver function; (iv) pedia-
tric patients (<15 years); and (v) elderly patients
(‡65 years).
Skin biopsy and inspection of the skin of the
patients with reduced renal function 3 months
after Gd-DOTA exposure were not planned in
this study.
Efficacy Evaluation
The efficacy of Gd-DOTA as an image-enhanc-
ing agent was assessed by the physician’s apprai-
sal according to the following four grades: (i) ‘very
effective’ (i.e. diagnostic performance highly im-
proved); (ii) ‘effective’ (i.e diagnostic performance
improved); (iii) ‘ineffective’ (i.e. examination per-
formed normally but diagnostic performance not
improved or necessary information for diagnosis
was not obtained); and (iv) ‘appraisal impossible’
(i.e. when no evaluable image was obtained as a
result of the movement and/or lack of coopera-
tion from the patient or when the MRI examin-
ation was not performed for whatever reason).
Statistical Evaluation
Descriptive statistics were used for patient base-
line characteristics and the frequency of adverse
reactions.
Paired t-test analyses were conducted on con-
tinuous data and chi-squared tests on categorical
data. All comparisons were considered significant
with a p-value of <0.05.
Results
Patient Characteristics and Datasets
Analyzed
This post-marketing surveillance studywas con-
ducted over 4 years (from March 2001 to March
2005). A total of 3480 survey forms were returned
from 127 participating institutions in Japan (mean
number of cases per institution was 27.4; range
5–100) [figure 1]. A total of 36 cases were excluded
from the analyses because of the inability to con-
firm continuous surveillance (n = 30), adminis-
tration of Gd-DOTA outside the survey period
Survey forms returned (n = 3480)
Subjects in safety dataset (n = 3444)
Subjects in efficacy dataset (n = 3426)
Reason for use was magnetic resonance imaging (n = 3426)
 - imaging of brain/spinal cord (n = 2044)
 - imaging of trunk/limbs (n = 1377)
 - imaging of brain/spinal cord and trunk/limbs (n = 5)
Subjects excluded from survey population (n = 36)
 - continuous surveillance could not be confirmed (n = 30)
 - administration not within agreed surveillance period (n = 4)
 - duplicate records (n = 2)
Subjects excluded from efficacy dataset because efficacy
appraisal impossible (n = 18)
  - images not evaluable (n = 9)
 - artefact or equipment malfunction (n = 4)
 - termination due to adverse reaction (n = 3)
 - injection-site extravasation (n = 1)
 - loss of clinical record (n = 1)
Fig. 1. Process to determine the datasets analyzed.
136 Ishiguchi & Takahashi
ª 2010 Ishiguchi & Takahashi, publisher and licensee Adis Data Information BV. Drugs R D 2010; 10 (3)
(n = 4) or duplicate results (n = 2). Among these
36 cases, two patients experienced adverse reac-
tions of mild intensity (nausea and injection-site
inflammation following extravasation). As these
two patients receivedGd-DOTA outside the period
defined in the contract with hospitals, they were
excluded from the safety dataset. Consequently, a
total of 3444 cases were included in the safety
dataset. The characteristics of these patients are
detailed in table I.
For the efficacy population, 18 cases were ex-
cluded from the safety dataset because of the follow-
ing reasons: images not evaluable (n = 9), artefact
or equipment malfunction (n = 4), termination
due to adverse reaction (n= 3), injection-site extra-
vasation (n = 1), or loss of clinical record (n = 1).
Accordingly, the efficacy population comprised
3426 cases (figure 1).
Safety
Adverse Reactions
A total of 40 adverse reactions were recorded
in 32 patients. The incidence of adverse reactions
was 0.93% (32 of 3444 patients) compared with
1.33% (11 of 829 patients) in trials conducted
prior to approval (table II). There were no serious
adverse reactions reported during the survey
period. Most of the 40 adverse reactions reported
were of mild intensity, except for four cases of
moderate intensity (two patients with nausea and
two with abnormal liver function).
The most frequently reported adverse reactions
in the current survey were gastrointestinal dis-
orders (0.49%), abnormal laboratory test results
(0.26%), and skin and subcutaneous tissue dis-
orders (0.15%) [table II]. The incidences of these
common adverse reactions found in trials con-
ducted before Gd-DOTA approval were 0.48%,
0%, and 0.48%, respectively.
Factors Affecting the Onset of Adverse Reactions
Among the 13 patient baseline characteristics
analyzed, sex, age, weight, status, indications, his-
tory of allergy/adverse drug reactions, and preme-
dication were not associated with a significantly
increased risk of adverse reactions. Conversely,
statistically significant risk factors for experienc-
ing adverse reactions were general condition, liver
Table I. Background summary of patients in the safety dataset
(n =3444)





<15; children 41 (1.19)
15 to <65 2015 (58.51)
‡65; elderly 1388 (40.30)
Weight [kg]
<40 119 (3.46)
40 to <50 605 (17.57)
50 to <60 1129 (32.78)








Brain/spinal cord 2051 (59.55)
Trunk/limbs 1387 (40.27)
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disorder, kidney disorder, complication, concomi-
tant treatments, and Gd-DOTA dose (table III).
As shown in table III, patients with ‘poor’
general condition had a greater risk of experienc-
ing an adverse reaction compared with those clas-
sified as ‘good’ or ‘fair’ (p = 0.0414).
Patients with liver and kidney disorders showed
a significantly higher (p < 0.0001) risk of experi-
encing an adverse reaction than patients without
liver and kidney disorders (see details in the
‘Patients with Specific Backgrounds’ section).
In addition, the incidence of adverse reactions
was statistically significantly higher for patients
with complications (p< 0.0003) than for those with
no complications.
Concomitant therapy was used by 1160 pa-
tients. Twenty of these patients experienced an
adverse reaction compared with only 12 of 2278
patients not using concomitant therapy. Simul-
taneous use of a concomitant drug was associated
with a statistically significantly higher incidence
of adverse reactions (p < 0.0005). The most fre-
quently used concomitant drugs were peptic ulcer
drugs (8.4%), vasodilators (6.2%), anti-hypertensive
drugs (5.2%), antiepileptic drugs (4.6%), and
adrenal hormone drugs (4.5%).
Finally, when analyzing the administration of
the Gd-DOTA dose, the incidence of adverse re-
actions was 0.93% (18 of 1941) in patients receiv-
ing Gd-DOTA >0.1–0.2mL/kg, and 0.84% (12 of
1437) in patients receiving Gd-DOTA >0.2mL/kg
(table III). No dose-dependent increase in the
incidence of adverse reactions was observed.
Patients with Specific Backgrounds
Patients Receiving Gd-DOTA >0.1mL/kg in Whom
the Kidney was the Imaging Target
MRI analysis of kidneys was performed in
60 patients and 52 of these patients received
Gd-DOTA >0.1mL/kg (mean Gd-DOTA dose
0.2176mL/kg; range 0.1176–0.4255mL/kg). No
patients experienced adverse reactions and the
results for the kidney function tests (serum crea-
tinine levels) performed in 24 patients were not
significantly different before and after Gd-DOTA
administration.
Patients with Decreased Kidney Function
Kidney disorders were reported by 98 patients
with mild to moderate renal impairment in most
cases. The incidence of adverse reactions was
significantly higher in patients with kidney dis-
orders than in those with normal kidney function
(table III; p < 0.0001). A total of ten adverse re-
actions (two cases of kidney disorders, two cases
of elevated serum creatinine, two cases of nausea,
and one case each of elevated blood urea, abnor-
mal kidney function tests, abnormal liver func-
tion tests, and sneezing) occurred in eight patients
with kidney disorders. Kidney function tests (con-
ducted during routine medical practice) revealed
no significant difference in serum creatinine and
BUN before and after Gd-DOTA administration
(table IV).
The incidence of adverse reactions was asso-
ciated with the type of kidney disorder (kidney
failure 25.00% [4 of 16 cases], diabetic nephropathy
20.00% [1 of 5], other 4.48% [3 of 67], nephritis 0%
[0 of 1]; p= 0.0282) and the severity of kidney disor-
ders (‘severe’ 30.00% [3 of 10], ‘moderate’ 13.33%
[2 of 15], ‘mild’ 4.17% [3 of 72]; p= 0.0154).
Patients with Impaired Liver Function
A total of 328 patients had impaired liver fun-
ction, whichwas considered to bemild tomoderate
Table I. Contd
Characteristic No. of patients (%)
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Table II. Incidence of acute non-renal adverse reactions (including infection) to meglumine gadoterate (Gd-DOTA) according to the system




No. of survey institutionsa 44 126 170
No. of cases in survey 829 3444 4273
No. of cases with ‡1 adverse reaction 11 32 43
No. of adverse reactions 17 40 57
Adverse reaction incidence (%) 1.33 0.93 1.01
Type of adverse reaction Incidence of adverse reactions classified by type [n (%)]
Neurologic disorder 5 (0.60) 1 (0.03) 6 (0.14)
Abnormal taste sensation 2 (0.24) 2 (0.05)
Headache 3 (0.36) 3 (0.07)
Tremorb 1 (0.03) 1 (0.02)
Visual disorder 1 (0.12) 1 (0.02)
Foreign body sensation in eye 1 (0.12) 1 (0.02)
Vascular disorder 1 (0.03) 1 (0.02)
Hemorrhaging of cranial tumorb 1 (0.03) 1 (0.02)
Respiratory, thoracic, or mediastinal
disorder
2 (0.06) 2 (0.05)
Coughing 1 (0.03) 1 (0.02)
Sneezing 1 (0.03) 1 (0.02)
Gastrointestinal disorder 4 (0.48) 17 (0.49) 21 (0.49)
Nausea 3 (0.36) 14 (0.41) 17 (0.40)
Vomiting 1 (0.12) 3 (0.09) 4 (0.09)
Hepatobiliary disorder 2 (0.06) 2 (0.05)
Abnormal liver functionb 2 (0.06) 2 (0.05)
Skin and subcutaneous tissue disorder 4 (0.48) 5 (0.15) 9 (0.21)
Drug eruption 1 (0.03) 1 (0.02)
Pruritus 1 (0.12) 1 (0.02)
Eruption 2 (0.24) 2 (0.06) 4 (0.09)
Urticaria 1 (0.12) 2 (0.06) 3 (0.07)
Renal and urinary disorder 2 (0.06) 2 (0.05)
Kidney disorderb 2 (0.06) 2 (0.05)
General disorder, administration site 3 (0.36) 1 (0.03) 4 (0.09)
Thoracic discomfort 1 (0.12) 1 (0.02)
Abnormal sensationb 1 (0.03) 1 (0.02)
Heat sensation 2 (0.24) 2 (0.05)
Laboratory tests 9 (0.26) 9 (0.21)
Elevated alanine aminotransferaseb 1 (0.03) 1 (0.02)
Elevated aspartate aminotransferaseb 1 (0.03) 1 (0.02)
Elevated blood creatinineb 2 (0.06) 2 (0.05)
Blood pressure decrease 1 (0.03) 1 (0.02)
Elevated blood ureab 1 (0.03) 1 (0.02)
Abnormal liver function test valuesb 2 (0.06) 2 (0.05)
Abnormal kidney function testsb 1 (0.03) 1 (0.02)
a The number of survey institutions is the total number of examination department units.
b Adverse reaction not listed in Summary of Product Characteristics (SPC) MedDRA version: 9.0.
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in most cases. The incidence of adverse reactions
was significantly higher in these patients than
in those with normal liver function (table III;
p< 0.0001). A total of 15 adverse reactions were
experienced by 12 patients with liver disorders
(four cases of nausea, two cases of abnormal liver
function, two cases of abnormal liver function
tests, one case each of elevated AST, elevated
ALT, kidney disorder, abnormal kidney function
tests, abnormal sensation, and two cases of drug
eruptions).
Liver function tests (when performed) before
and after Gd-DOTA administration revealed a
statistically significant decrease in test values for
LDH after administration (n = 178; 362.3 IU/L
vs 341.1 IU/L, respectively; p= 0.0429), but var-
iations in the levels of AST, ALT, ALP, g-GT,
and total bilirubin were not significant (table IV).
No significant difference in the incidence of ad-
verse reactions was observed according to un-
derlying causal factor or the severity of the liver
disorder.
Pediatric Patients (<15 years)
There were 41 pediatric patients (age range from
1 month to 14 years and 11 months) at the time of
Gd-DOTA administration. The recommended
dose of Gd-DOTA is 0.1mmol/kg (0.2mL/kg) for
adults, children, and infants. The average dose of
Gd-DOTA administered was 0.2049mL/kg. Two
Table III. Patient background risk factors associated with statistically significant differences in adverse reaction rates
Characteristic No. of cases
in survey







Good 1610 8 (0.50) 11 (0.68) 0.0414 (df = 3)
Fair 1596 19 (1.19) 23 (1.44)
Poor 233 5 (2.15) 6 (2.58)
Very poor 4 0 (0.00) 0 (0.00)
Unknown 1 0 (0.00) 0 (0.00)
Liver disorder
No 2658 18 (0.68) 22 (0.83) 0.0001 (df = 1)
Yes 328 12 (3.66) 15 (4.57)
Unknown 458 2 (0.44) 3 (0.66)
Kidney disorder
No 2936 23 (0.78) 28 (0.95) 0.0001 (df = 1)
Yes 98 8 (8.16) 10 (10.20)
Unknown 410 1 (0.24) 2 (0.49)
Complication
No 1874 9 (0.48) 11 (0.59) 0.0003 (df = 1)
Yes 1141 21 (1.84) 26 (2.28)
Unknown 429 2 (0.47) 3 (0.70)
Concomitant drugs
No 2278 12 (0.53) 13 (0.57) 0.0005 (df = 1)
Yes 1160 20 (1.72) 27 (2.33)
Unknown 6 0 (0.00) 0 (0.00)
Gd-DOTA dose [mL/kg]
£0.1 8 1 (12.50) 1 (12.50) 0.0026 (df = 2)
>0.1–0.2 1941 18 (0.93) 24 (1.24)
>0.2 1437 12 (0.84) 14 (0.97)
Unknown 58 1 (1.72) 1 (1.72)
df = degrees of freedom; Gd-DOTA =meglumine gadoterate.
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children received a dose that was approximately
1.7-fold and 1.9-fold greater than the recom-
mended dose (0.2mL/kg) for brain/spinal cord
imaging in both cases. No adverse reactions were
reported for any of the pediatric patients.
Elderly Patients (‡65 years)
Patients aged ‡65 years accounted for 40.3%
of patients of the survey (1388 of 3444; table I).
The incidence of adverse reactions was not signi-
ficantly different between those aged ‡65 years
and those aged 16–64 years (0.79% vs 1.02%;
p= 0.492).
Efficacy
According to the physician’s appraisal, Gd-
DOTA was scored as ‘very effective’ or ‘effective’
in the majority of patients (1075 and 2335 cases,
respectively, of 3426 cases in total). Gd-DOTA was
considered to be ‘ineffective’ in only 16 cases. The
overall efficacy ratewas 99.53% (3410 of 3426 cases),
which was similar to the results obtained in trials
conducted prior to approval (efficacy rate 90.21%
[553 of 613]).
Analysis of the factors affecting efficacy re-
vealed that the presence of kidney disorders was
associated with a statistically significantly greater
likelihood of inefficacy (2.08% vs 0.44% for patients
without kidney disorders; p = 0.0247). Other pa-
tient characteristics (including sex, age, weight,
indications, liver disorder, Gd-DOTA dose) were
not associated with any significant differences in
efficacy (table V).
Discussion
This mandatory post-marketing surveillance
survey was designed to assess the safety and effi-
cacy of Gd-DOTA for brain/spinal cord and/or
trunk/limb imaging in a wide range of patients,
following its registration in Japan in September
2000. The results presented in this article show
that Gd-DOTA, as used in clinical practice, was
associated with a low rate of adverse reactions
(<1%) and was effective as an image-enhancing
agent in the majority of patients.
This survey was also designed to identify risk
factors for the development of adverse reactions.
The analysis showed that statistically significant
risk factors for adverse reactions were general con-
dition, liver disorders, kidney disorders, compli-
cations, concomitant treatments, and Gd-DOTA
dose (although the incidence of adverse reactions
was not dose dependent). However, these data
should be interpreted cautiously in view of the
small number of patients for whom historical and
clinical data were available at screening in this
study.
The incidence of adverse reactions following
Gd-DOTA administration in the majority of pub-
lished studies to date is less than 1%, ranging from
0.4%[13] to 0.97%.[14] The one notable exception is
a reported incidence of 17.3%;[15] however, in this
Table IV. Variation in kidney and liver function test values before and after meglumine gadoterate (Gd-DOTA) administration in patients with
decreased kidney or liver function






Kidney function test values in patients with decreased kidney function
Serum creatinine (mg/dL) 66 2.2 – 2.2 2.3 –2.2 0.5763
BUN (mg/dL) 66 32.8 – 21.3 31.3 –21.7 0.3981
Liver function test values in patients with decreased liver function
AST (IU/L) 205 80.0 – 110.9 75.9 –124.7 0.5208
ALT (IU/L) 205 96.1 – 171.2 88.9 –171.6 0.4278
ALP (IU/L) 161 385.4 – 294.1 397.0 – 325.1 0.3420
LDH (IU/L) 178 362.3 – 342.1 341.1 – 274.5 0.0429*
g-GT (IU/L) 164 131.4 – 203.7 120.9 – 166.9 0.1570
Total bilirubin (mg/dL) 176 1.2 – 1.3 1.4 –1.9 0.1461
ALP =alkaline phosphatase; BUN = blood urea nitrogen; LDH = lactate dehydrogenase; c-GT = g-glutamyl transferase; * p <0.05.
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Table V. Summary of efficacy trial results classified according to risk factors
Characteristic Efficacy [n] Ineffective rate [%]
(no. of cases)
p-Value (chi-squared
test value)very effective effective ineffective
Sex
Male 530 1152 9 0.53 (9/1671) 0.5805 (df = 1)
Female 545 1183 7 0.40 (7/1735)
Total 1075 2335 16 0.47 (16/3426)
Age [y]
<65; not elderly 644 1398 7 0.34 (7/2049) 0.1891 (df = 1)
‡65; elderly 431 937 9 0.65 (9/1377)
Total 1075 2335 16 0.47 (16/3426)
Weight [kg]
<40 42 77 0 0.00 (0/119) 0.6924 (df = 4)
40 to <50 184 416 4 0.66 (4/606)
50 to <60 363 753 7 0.62 (7/1123)
60 to <70 317 658 3 0.31 (3/978)
‡70 157 377 2 0.37 (2/536)
Unknown 12 54 0 0.00 (0/66)
Total 1075 2335 16 0.47 (16/3426)
Indications
Brain/spinal cord 551 1487 6 0.29 (6/2044) 0.1885 (df = 2)
Trunk/limbs 522 845 10 0.73 (10/1377)
Brain/spinal cord and
trunk/limbs
2 3 0 0.00 (0/5)
Total 1075 2335 16 0.47 (16/3426)
Liver disorders
No 834 1796 11 0.42 (11/2644) 0.2117 (df = 1)
Yes 99 225 3 0.92 (3/327)
Unknown 139 314 2 0.44 (2/455)
Total 1075 2335 16 0.47 (16/3426)
Kidney disorders
No 929 1981 13 0.44 (13/2923) 0.0247* (df = 1)
Yes 26 68 2 2.08 (2/96)
Unknown 120 286 1 0.25 (1/407)
Total 1075 2335 16 0.47 (16/3426)
Gd-DOTA dose [mL/kg] – patients without kidney disorders
<0.125 3 12 0 0.00 (0/15) 0.6671 (df = 5)
0.125 to <0.175 76 140 0 0.00 (0/216)
0.175 to <0.225 704 1626 13 0.55 (13/2343)
0.225 to <0.275 128 220 0 0.00 (0/348)
0.275 to <0.325 56 127 1 0.54 (1/184)
‡0.325 75 132 1 0.48 (1/208)
Unknown 11 42 0 0.00 (0/53)
Total 1053 2299 15 0.45 (15/3367)
Continued next page
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study, the authors noted that 71% of adverse re-
actions were reported 24 hours after the procedure,
which, due to the rapid clearance rate reported
for gadolinium-based contrast agents, raises the
question as to whether these events were drug re-
lated. The most frequently reported adverse reac-
tions in our post-marketing surveillance survey
were gastrointestinal disorders (0.49% compared
with 0.48% in previous trials conducted before
Gd-DOTA approval), laboratory test abnormal-
ities (0.26%), and skin and subcutaneous tissue
disorders (0.15% compared with 0.48% in previous
trials). Most of the reported adverse reactions
were of mild intensity and there were no serious
adverse reactions. The results of the current survey
are in agreement with a large-scale post-marketing
surveillance study conducted in Germany.[13]
Herborn et al.[13] reported that minor adverse events
occurred infrequently (0.4%; 94/24 308 patients)
and included nausea (0.17%; 42/24 308 patients),
vomiting (0.05%; 13/24 308 patients), feeling of
warmth (0.020%; six patients), and taste altera-
tions (0.02%; four patients). Interestingly, patients
with liver disease experienced nausea after Gd-
DOTA injection significantly more frequently than
any other subgroup (p< 0.001) but for unknown
reasons.
Anaphylactoid reactions induced by gadolinium-
containing products are rare and although >15 mil-
lion patients worldwide have been exposed to
Gd-DOTA, there are few published case reports
of anaphylactic shock following Gd-DOTA ad-
ministration. The occurrence of anaphylactic shock
in one patient during a large-scale post-marketing
surveillance study of Gd-DOTA allowed Herborn
and colleagues[13] to calculate the incidence of ana-
phylactic shock associated with Gd-DOTA as
0.004%. Indeed, to our knowledge, only four cases
of anaphylactic shock have been published[13,16,17]
and, in every case, the patient developed an imme-
diate reaction to Gd-DOTA despite the absence of
any history of allergy. No patients in the present
study experienced an anaphylactoid reaction follow-
ing Gd-DOTA administration, although 4.44%
of patients had a history of allergy or adverse
drug reactions.
Several recent publications[7,18-21] have sug-
gested an association between administration of
gadolinium-based contrast agents and NSF, and
there appears to be a difference between the var-
ious contrast agents in their trigger of NSF.[22]
Cyclic gadolinium-based contrast agents (such
as Gd-DOTA and others) are more stable and
less likely to release free gadolinium3+,[23] and to
our knowledge, no validated case of NSF has been
solely attributed to Gd-DOTA. Based on the re-
sults obtained in the current survey and our study
design, which did not allow accurate assessment
of NSF, it is difficult to draw conclusions about
NSF risk for this study. Tsushima et al.[24] sug-
gested that the small number of reported cases of
NSF in Japan compared with the US and Europe
can be attributed to the uncommon use of high-
dose (>0.2mmol/kg) administration of gadolinium-
based contrast agents.
The 99.53% global efficacy rate reported in the
present study is in line with the study conducted
by Herborn et al.[13] in which the efficacy of Gd-
DOTA was rated as ‘excellent’ or ‘very good’ in
the majority of cases (97.5%). Interestingly, the
present survey demonstrated a significantly greater
likelihood of inefficacy associated with kidney
disorders, whereas Herborn et al.[13] found that
image quality was significantly poorer in patients
Table V. Contd
Characteristic Efficacy [n] Ineffective rate [%]
(no. of cases)
p-Value (chi-squared
test value)very effective effective ineffective
Gd-DOTA dose [mL/kg] – patients with kidney disorders
£0.1 3 3 0 0.00 (0/6) 0.7319 (df = 1)
>0.1 19 32 1 1.92 (1/52)
Unknown 0 2 0 0.00 (0/2)
Total 22 37 1 1.67 (1/60)
df = degrees of freedom; Gd-DOTA = gadoterate meglumine; * p <0.05.
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with a body mass index >25kg/m2 (p< 0.001). Un-
fortunately, detailed reasons for the inefficacy
associated with kidney disorder were not declared
during our study.
This study is not free of limitations. Logistic
regression analysis for evaluating the confound-
ing factors on the onset of adverse reactions was
not performed. This post-marketing surveillance
study was limited by a lack of clear definitions of
general condition and complications that would
ensure homogeneity between sites. As contrast-
induced nephropathy (CIN) has become a signif-
icant source of hospital morbidity, CIN incidence
and risk factors have not been evaluated in this
survey. Another limitation of this post-marketing
surveillance study was the evaluation of only ac-
ute non-renal adverse reactions and not delayed
ones. Thus, it seems likely that some adverse re-
actions may have been missed and underreported
in this patient cohort. Finally, the use of question-
naires for data collection in such a study limits
the quality of the results compared with control-
led clinical trials.
Conclusion
Overall, this post-marketing surveillance study
did not reveal any untoward or unexpected find-
ings concerning the safety or efficacy of Gd-DOTA.
The low incidence of adverse reactions (<1%) and
the absence of serious adverse reactions reported
during the survey period showed that Gd-DOTA
was very well tolerated. In conclusion, the use of
Gd-DOTA as an MRI-enhancing contrast me-
dium in the clinical practice setting appears to be
safe and effective.
Acknowledgments
The authors would like to thank all the 127 institutions
that participated in this Magnescope post-marketing sur-
veillance study. This post-marketing surveillance study was
supported by the Guerbet group. The authors have no con-
flicts of interest that are directly relevant to the contents of this
study.
References
1. Idee JM, PortM, Raynal I, et al. Clinical and biological con-
sequences of transmetallation induced by contrast agents
for magnetic resonance imaging: a review. Fundam Clin
Pharmacol 2006; 20 (6): 563-76
2. Ruehm SG, Goyen M, Barkhausen J, et al. Rapid magnetic
resonance angiography for detection of atherosclerosis.
Lancet 2001; 357 (9262): 1086-91
3. Claussen C, Laniado M, Schorner W, et al. Gadolinium-
DTPA in MR imaging of glioblastomas and intracranial
metastases. AJNR Am J Neuroradiol 1985; 6 (5): 669-74
4. Healy ME, Hesselink JR, Press GA, et al. Increased detec-
tion of intracranial metastases with intravenous Gd-DTPA.
Radiology 1987; 165 (3): 619-24
5. Meaney JF, Weg JG, Chenevert TL, et al. Diagnosis of pul-
monary embolism with magnetic resonance angiography.
N Engl J Med 1997; 336 (20): 1422-7
6. Semelka RC, Helmberger TK. Contrast agents for MR im-
aging of the liver. Radiology 2001; 218 (1): 27-38
7. Thomsen HS, Marckmann P, Logager VB. Nephrogenic
systemic fibrosis (NSF): a late adverse reaction to some of
the gadolinium based contrast agents. Cancer Imaging
2007; 7: 130-7
8. Grobner T. Gadolinium: a specific trigger for the develop-
ment of nephrogenic fibrosing dermopathy and nephroge-
nic systemic fibrosis? Nephrol Dial Transplant 2006; 21 (4):
1104-8
9. Kirchin MA, Runge VM. Contrast agents for magnetic res-
onance imaging: safety update. Top Magn Reson Imaging
2003; 14 (5): 426-35
10. Laurent S, Elst LV, Muller RN. Comparative study of the
physicochemical properties of six clinical low molecular
weight gadolinium contrast agents. Contrast Media Mol
Imaging 2006; 1 (3): 128-37
11. Port M, Idee JM, Medina C, et al. Stability of gadolinium
chelates and their biological consequences: new data and
some comments. Br J Radiol 2008; 81 (963): 258-9
12. Allard M, Doucet D, Kien P, et al. Experimental study of
DOTA-gadolinium: pharmacokinetics and pharmacologic
properties. Invest Radiol 1988; 23 (1): S271-4
13. Herborn CU, Honold E, Wolf M, et al. Clinical safety and
diagnostic value of the gadolinium chelate gadoterate me-
glumine (Gd-DOTA). Invest Radiol 2007; 42 (1): 58-62
14. OudkerkM, Sijens PE, Van Beek EJ, et al. Safety and efficacy
of dotarem (Gd-DOTA) versus magnevist (Gd-DTPA) in
magnetic resonance imaging of the central nervous system.
Invest Radiol 1995; 30 (2): 75-8
15. Brugieres P, Gaston A, Degryse HR, et al. Randomised
double blind trial of the safety and efficacy of two gadolinium
complexes (Gd-DTPA and Gd-DOTA). Neuroradiology
1994; 36 (1): 27-30
16. Beaudouin E, Kanny G, Blanloeil Y, et al. Anaphylactic
shock induced by gadoterate meglumine (DOTAREM).
Eur Ann Allergy Clin Immunol 2003; 35 (10): 382-5
17. Hasdenteufel F, Luyasu S, Renaudin JM, et al. Anaphylac-
tic shock after first exposure to gadoterate meglumine: two
case reports documented by positive allergy assessment.
J Allergy Clin Immunol 2008; 121 (2): 527-8
18. DeHoratius DM, Cowper SE. Nephrogenic systemic fibro-
sis: an emerging threat among renal patients. Semin Dial
2006; 19 (3): 191-4
19. Cowper SE. Nephrogenic fibrosing dermopathy: the first
6 years. Curr Opin Rheumatol 2003; 15 (6): 785-90
144 Ishiguchi & Takahashi
ª 2010 Ishiguchi & Takahashi, publisher and licensee Adis Data Information BV. Drugs R D 2010; 10 (3)
20. Scheinfeld N. Nephrogenic fibrosing dermopathy: a compre-
hensive review for the dermatologist. Am J Clin Dermatol
2006; 7 (4): 237-47
21. Cowper S. Nephrogenic fibrosing dermopathy [online]. Avail-
able from URL: http://www.icnfdr.org [Accessed 2010
Aug 27]
22. Penfield JG, Reilly RF. Nephrogenic systemic fibrosis risk:
is there a difference between gadolinium-based contrast
agents? Semin Dial 2008; 21 (2): 129-34
23. Kimura J, Ishiguchi T, Matsuda J, et al. Human compara-
tive study of zinc and copper excretion via urine after admi-
nistration of magnetic resonance imaging contrast agents.
Radiat Med 2005; 23 (5): 322-6
24. TsushimaY,Takahashi-TaketomiA,EndoK.Nephrogenic sys-
temic fibrosis in Japan: advisability of keeping the administered
dose as low as possible. Radiology 2008; 247 (3): 915-6
Correspondence: Dr Tsuneo Ishiguchi, Professor of Depart-
ment of Radiology, Aichi Medical University, 21 Nagakute-
cho, Aichi-gun, Aichi-ken 480-1195, Japan.
E-mail: ishiguti@aichi-med-u.ac.jp
Post-Marketing Data for Gd-DOTA in Japan 145
ª 2010 Ishiguchi & Takahashi, publisher and licensee Adis Data Information BV. Drugs R D 2010; 10 (3)
